2023.03.13
On March 10, 2023, Livzon Pharmaceutical Group Inc. ("Livzon") announced that it had signed an exclusive license agreement with South Korea-based Onconic Therapeutics Inc. ("Onconic") to develop, license and manufacture its potassium-competitive acid blocker in China.
JunHe was engaged by Livzon to draft, review, revise and negotiate the agreement and won the trust of the client for its consistently professional and efficient services.
The JunHe team was led by partner LI, Qi (Adam) with the assistance of partner ZHAO, Hao (Gerry).